Your Messages Inbox (38) 
Your Unread Messages
See All
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Robertson JFR et al. – Fulvestrant may be a suitable treatment option in extensively pre-treated patients with HER2-positive, hormone receptor-positive ABC.
Methods- Clinical experience data from 10 treatment centres pooled
- Postmenopausal patients with predominantly hormone receptor-positive and HER2-positive disease included
- Clinical benefit (CB) was defined as the proportion of patients achieving a response to treatment (partial or complete) or stable disease lasting ≥ 6 months
- Data for 102 patients analysed
- Fulvestrant resulted in overall CB rate of 42% (43/101) in HER2-positive patients and 40% (25/63) in patients with visceral disease
- Median duration of treatment 14.5 months (range 6–44 months)
- Fulvestrant showed activity up to fourth line of endocrine therapy and up to seventh line of overall therapy
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09
The association of metabolic syndrome with triple-negative breast cancer
Breast Cancer Research and Treatment, 10/28/09
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Sponsor
Article Search
Sponsor
Sponsor